|
|
|
|
|
|
|
|
press release
Vermillion and ASPiRA LABs Applaud the FDA's Position on Ovarian Cancer Screening
AUSTIN, Texas, Sept. 9, 2016 /PRNewswire/ -- ASPiRA LABs, a Vermillion company (NASDAQ: VRML),
today announced its support for the recent US Food and Drug
Administration (FDA) safety communication which recommends against the
use of any screening tests for ovarian cancer.
Earlier this week, the FDA announced
that it is alerting women about the risks associated with the use of
tests being marketed as ovarian cancer screening tests. The Agency
stated that it is especially concerned about delaying effective
preventive treatments for women who show no symptoms, but who are still
at increased risk for developing ovarian cancer.
As the medical community knows, ASPiRA LABs' FDA cleared technologies, OVA1® and Overa™, are NOT screening tests. OVA1/Overa are FDA cleared technologies to assess risk of ovarian cancer malignancy for women who present with a pelvic mass and are planned for surgery........
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.